Viatris Inc.VTRSNASDAQ

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

prnewswire.com

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies.

zacks.com

Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?

Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

globenewswire.com

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference

zacks.com

Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates

VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.

prnewswire.com

Viatris Provides Pipeline Update on Four Regulatory Milestones

Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for Low Dose Estrogen Weekly Patch for Contraception U.S. FDA Clears Investigational New Drug Application for MR-146 in Neurotrophic Keratopathy Japan Pharmaceuticals and Medical Devices Agency Accepts Japanese New Drug Application Filing for Pitolisant in Obstructive Sleep Apnea Syndrome PITTSBURGH , Dec. 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: Octreotide Acetate for Injectable Suspension: The U.S. Food and Drug Administration (FDA) has approved the Company's octreotide acetate for injectable suspension, a generic version of Sandostatin® LAR Depot. The therapy is indicated for treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with Vasoactive Intestinal Peptide secreting tumors.

prnewswire.com

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH , Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026.

prnewswire.com

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions PITTSBURGH , Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of Viatris' equity stake in Biocon Biologics Limited ("Biocon Biologics"). Under the definitive agreements, Biocon will acquire all of Viatris' convertible preferred equity in Biocon Biologics for total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon.

gurufocus.com

Mark Cuban Takes Aim at FDA Fees

Viatris (VTRS) and Teva Pharma (TEVA) could soon face fresh competition after billionaire entrepreneur Mark Cuban called on Washington to scrap a fee he says is

seekingalpha.com

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

seekingalpha.com

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

globenewswire.com

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in 8th Annual Evercore Annual Healthcare Conference Management to Participate in 8th Annual Evercore Annual Healthcare Conference

prnewswire.com

Viatris to Participate in Upcoming Investor Conferences

PITTSBURGH , Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in December 2025. The Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:30 a.m.

prnewswire.com

Európska štúdia zisťuje klesajúce ceny, rastúce náklady a nedostatky - Viatris a Medicines for Europe prezentujú nezávislú štúdiu počas Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR)

/PRNewswire/ - S príchodom Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR) uvádza Svetová zdravotnícka organizácia vo svojej Globálnej správe o

prnewswire.com

Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden

/PRNewswire/ -- Zu Beginn der Weltwoche zur Sensibilisierung für Antibiotikaresistenzen (AMR) zeigt der globale Bericht der Weltgesundheitsorganisation zur

prnewswire.com

Europejskie badanie pokazuje spadające ceny, rosnące koszty i niedobory - wyniki niezależnego badania przedstawione podczas Światowego Tygodnia Wiedzy o Antybiotykach przez firmę Viatris i organizację Medicines for Europe

/PRNewswire/ -- Wraz z rozpoczęciem Światowego Tygodnia Wiedzy o Antybiotykach (World AMR Awareness Week) raport Światowej Organizacji Zdrowia z 2025 r. na

seekingalpha.com

Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Viatris Inc. ( VTRS ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Scott Smith - CEO & Director Theodora Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Hi. Good morning.

prnewswire.com

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

PITTSBURGH , Nov. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025 . The list of 25 global leaders was selected from organizations that participated in Great Place To Work's employee survey process, with over 9 million responses representing more than 25 million employees worldwide.

seekingalpha.com

Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Viatris Inc. ( VTRS ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma.

seekingalpha.com

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Viatris Inc. ( VTRS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants William Szablewski Scott Smith - CEO & Director Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Viatris Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

zacks.com

Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance

Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance